cs.AINov 14, 2026

From Mutation to Medication: Characterizing Failures of Clinical LLMs to Respect Genomic Resistance

Authors: Negin Ashrafi, Roxana Daneshjou

Organizations: Stanford University, Stanford, CA, USA

Abstract

Language models are increasingly proposed to support molecular tumour boards, but may recommend cancer therapies despite genomic evidence of resistance. We evaluated ten models on 1,464 resistance cases from five curated oncology knowledge bases, collecting 58,910 judgments. Models endorsed resisted therapies in 21.8-81.4% of cases. However, raw rates can reflect a tendency to agree rather than an ability to distinguish resistance from drug sensitivity: one open-weight model endorsed 81.4% of resistance cases and 82.3% of sensitivity controls. We therefore compared endorsement within matched gene and evidence-level groups. This analysis is exploratory because it was specified after the pre-registered analysis, which yielded null-to-weak results. Measured failures depended strongly on the reference knowledge base and evidence strength. When a second source independently confirmed resistance, four models across three vendors endorsed at most 2.4% of cases; at weaker evidence tiers, discrimination was not measurable. Models sometimes acknowledged resistance yet recommended the therapy. Repeating a model's own resistance conclusion reduced endorsement to 0.0-3.5% on cases where it had stated resistance. Falsely attributing the opposite conclusion increased endorsement above baseline for all seven hosted models, reaching 95.2% for GPT-4o; an instruction without an attributed conclusion changed endorsement by only 0.9 percentage points. Providing the correct curated evidence reduced unqualified strong recommendations to 0.3-3.5%, testing evidence use under an oracle condition rather than retrieval.

Explore similar work

Oct 1, 2026

OpenMTB-Audit: Exposing Over-Refusal and Clinical Expert Perspectives in LLM-Based Molecular Tumor Board Safety Evaluation

Molecular tumor boards integrate genomic findings, clinical context, and therapeutic evidence to support precision oncology. As AI enters this workflow, a key safety challenge is distinguishing truly unsupported recommendations from evidence-supported options that still require oncologist review because of incomplete information, poor ECOG performance status, or other clinical caveats. We introduce OpenMTB-Audit, an open-source benchmark of 500 synthetic non-small cell lung cancer cases spanning five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. Across eight large language model configurations, we identify pervasive over-refusal: all LLM configurations failed to retain the Partially Supported label in 83.3-100% of true Partially Supported cases, achieving high aggregate safety scores through label collapse rather than clinically calibrated reasoning. To address this limitation, we developed MTB-AuditAgent, a deterministic seven-module framework separating evidence verification, missing-information detection, safety classification, and abstention. It reduces over-refusal to 6.7% and achieves 91.2% accuracy (95% CI: 88.6-93.6%). A two-oncologist annotation study found disagreement concentrated at the boundary between information sufficiency and treatment optimization, underscoring the need to preserve clinically meaningful distinctions.
Jul 13, 2026

Agentic systems for breast cancer treatment recommendations

Large language models (LLMs) are increasingly being explored for clinical decision support, but their reliability in complex oncology treatment planning remains unclear. We evaluated agentic LLM systems for breast cancer treatment recommendation generation using 72 real clinical cases across stages I to IV and 1,147 case-specific rubrics generated through Asymmetric Information Rubric Generation (AIRG), in which the rubric generator had access to real clinical decisions unavailable to the evaluated models. Seven pipelines were compared, including single-LLM baselines, tool-augmented systems, and multi-agent architectures with fact checking and autonomous subagent spawning. The best-performing configuration, Claude Opus 4.8 with the D&C+SA pipeline, achieved a global score of 0.594 ±\pm 0.025. Tool use and increased agent autonomy had mixed effects, improving performance in some settings but degrading it in others. Performance varied by clinical domain and disease stage, and oncologist-led error analysis revealed persistent clinically relevant failures, including incorrect or missing recommendations, flawed justifications, citation errors, outdated claims, and overconfidence. These findings suggest that agentic LLM systems can generate clinically relevant breast cancer recommendations, but remain insufficient for unsupervised clinical use.
Sep 29, 2026

Sense and Sensitivity: Benchmarking LLM Clinical Triage Recommendations with Physician Experts

As large language models (LLMs) are increasingly used in clinical settings, it is critical to evaluate their reliability under realistic variation in clinical text. We study this question in clinical triage, comparing LLMs to practicing physicians under text perturbations that preserve the underlying clinical setting. We introduce a benchmark of over 6,000 clinical scenarios, 7,000 physician annotations, and 225,000 model responses. Using this benchmark, we make two key observations. First, LLMs are more likely than physicians to recommend unnecessary care at baseline, and this tendency increases under perturbed inputs. Further, we find that LLM recommendations are more sensitive to gender and tone perturbations than human recommendations. Together, these results demonstrate that LLMs can vary under clinically irrelevant textual changes, highlighting the need for deployment-oriented evaluations grounded in expert physician behavior.